Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease

J Med Microbiol. 2009 Mar;58(Pt 3):371-373. doi: 10.1099/jmm.0.006809-0.

Abstract

We present a case of Mycobacterium kansasii olecranon bursitis in a woman with known immunosuppression secondary to the treatment received for her Behçet's disease. We found only one other case report of olecranon bursitis caused by M. kansasii in the literature, which, unlike our case, presented in an immunocompetent adult following trauma. This case extends the range of opportunistic mycobacterial infections that are associated with anti-tumour necrosis factor therapy.

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antitubercular Agents / therapeutic use
  • Behcet Syndrome / complications*
  • Behcet Syndrome / drug therapy
  • Behcet Syndrome / immunology
  • Bursitis / drug therapy
  • Bursitis / immunology
  • Bursitis / microbiology*
  • Elbow
  • Ethambutol / therapeutic use
  • Female
  • Humans
  • Immunocompromised Host
  • Infliximab
  • Middle Aged
  • Mycobacterium Infections, Nontuberculous / drug therapy
  • Mycobacterium Infections, Nontuberculous / immunology
  • Mycobacterium Infections, Nontuberculous / microbiology*
  • Mycobacterium kansasii* / isolation & purification
  • Rifampin / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antitubercular Agents
  • Ethambutol
  • Infliximab
  • Rifampin